Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
9-peptide breast cancer vaccine
- Development stage
- Phase 1
- Lead developer
- UVA Comprehensive Cancer Center
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Administration
- Injection
01
Overview
The 9-peptide breast cancer vaccine is an investigational peptide-based immunotherapy developed by Craig L. Slingluff Jr. and colleagues at the University of Virginia. It is designed to induce a multi-antigenic T-cell response against micrometastatic disease in patients with stage I-IV breast cancer. The vaccine consists of nine MHC class I-restricted peptides derived from six tumor-associated antigens: MAGE-A1, MAGE-A3, MAGE-A10, carcinoembryonic antigen (CEA), NY-ESO-1, and HER2. To enhance immunogenicity, the vaccine is administered in combination with poly-ICLC, a Toll-like receptor 3 (TLR3) agonist that serves as an adjuvant, and a helper peptide derived from tetanus toxoid to provide CD4+ T-cell support.
- Other names
- 9-peptide breast cancer vaccine plus poly-ICLC9-peptide vaccine
02
Targets
MHC I (MHC class I})MHC II (Major histocompatibility complex class II receptor)TLR3 (Toll-like receptor 3)NY-ESO-1 (New york esophageal squamous cell carcinoma 1)CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)ERBB2 (Erb-b2 receptor tyrosine kinase 2)MAGEA1 (Melanoma-associated antigen 1)MAGEA10 (Melanoma-associated antigen family member A10)MAGEA3 (Melanoma-associated antigen 3)
Beyond the preview
Go deeper on 9-peptide breast cancer vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 9-peptide breast cancer vaccine.